vs

Side-by-side financial comparison of UTAH MEDICAL PRODUCTS INC (UTMD) and Xos, Inc. (XOS). Click either name above to swap in a different company.

UTAH MEDICAL PRODUCTS INC is the larger business by last-quarter revenue ($9.0M vs $5.2M, roughly 1.7× Xos, Inc.). UTAH MEDICAL PRODUCTS INC runs the higher net margin — 28.4% vs -186.8%, a 215.2% gap on every dollar of revenue. On growth, UTAH MEDICAL PRODUCTS INC posted the faster year-over-year revenue change (-1.2% vs -54.5%). Over the past eight quarters, UTAH MEDICAL PRODUCTS INC's revenue compounded faster (-10.7% CAGR vs -35.7%).

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.

UTMD vs XOS — Head-to-Head

Bigger by revenue
UTMD
UTMD
1.7× larger
UTMD
$9.0M
$5.2M
XOS
Growing faster (revenue YoY)
UTMD
UTMD
+53.3% gap
UTMD
-1.2%
-54.5%
XOS
Higher net margin
UTMD
UTMD
215.2% more per $
UTMD
28.4%
-186.8%
XOS
Faster 2-yr revenue CAGR
UTMD
UTMD
Annualised
UTMD
-10.7%
-35.7%
XOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
UTMD
UTMD
XOS
XOS
Revenue
$9.0M
$5.2M
Net Profit
$2.6M
$-9.8M
Gross Margin
58.2%
-50.5%
Operating Margin
27.0%
-186.6%
Net Margin
28.4%
-186.8%
Revenue YoY
-1.2%
-54.5%
Net Profit YoY
-11.6%
48.6%
EPS (diluted)
$0.80
$-0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
UTMD
UTMD
XOS
XOS
Q4 25
$9.0M
$5.2M
Q3 25
$9.8M
$16.5M
Q2 25
$10.0M
$18.4M
Q1 25
$9.7M
$5.9M
Q4 24
$9.2M
$11.5M
Q3 24
$10.0M
$15.8M
Q2 24
$10.4M
$15.5M
Q1 24
$11.3M
$12.6M
Net Profit
UTMD
UTMD
XOS
XOS
Q4 25
$2.6M
$-9.8M
Q3 25
$2.6M
$2.1M
Q2 25
$3.0M
$-7.5M
Q1 25
$3.0M
$-10.2M
Q4 24
$2.9M
$-19.0M
Q3 24
$3.6M
$-10.5M
Q2 24
$3.5M
$-9.7M
Q1 24
$4.0M
$-11.0M
Gross Margin
UTMD
UTMD
XOS
XOS
Q4 25
58.2%
-50.5%
Q3 25
57.1%
15.3%
Q2 25
56.2%
8.8%
Q1 25
57.0%
20.6%
Q4 24
58.1%
-32.4%
Q3 24
58.0%
18.1%
Q2 24
60.1%
13.1%
Q1 24
59.7%
22.1%
Operating Margin
UTMD
UTMD
XOS
XOS
Q4 25
27.0%
-186.6%
Q3 25
26.6%
-42.4%
Q2 25
32.1%
-38.5%
Q1 25
32.5%
-157.7%
Q4 24
32.0%
-127.0%
Q3 24
33.4%
-61.4%
Q2 24
33.1%
-73.2%
Q1 24
34.2%
-81.1%
Net Margin
UTMD
UTMD
XOS
XOS
Q4 25
28.4%
-186.8%
Q3 25
26.8%
12.9%
Q2 25
30.6%
-40.8%
Q1 25
31.3%
-173.3%
Q4 24
31.7%
-165.4%
Q3 24
35.6%
-66.6%
Q2 24
33.2%
-62.2%
Q1 24
34.9%
-87.1%
EPS (diluted)
UTMD
UTMD
XOS
XOS
Q4 25
$0.80
$-0.76
Q3 25
$0.82
$0.22
Q2 25
$0.94
$-0.91
Q1 25
$0.92
$-1.26
Q4 24
$0.86
$-2.34
Q3 24
$1.03
$-1.32
Q2 24
$0.98
$-1.23
Q1 24
$1.09
$-1.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
UTMD
UTMD
XOS
XOS
Cash + ST InvestmentsLiquidity on hand
$85.8M
$14.0M
Total DebtLower is stronger
$225.0K
Stockholders' EquityBook value
$119.3M
$23.3M
Total Assets
$122.5M
$60.4M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
UTMD
UTMD
XOS
XOS
Q4 25
$85.8M
$14.0M
Q3 25
$84.3M
$14.1M
Q2 25
$82.2M
$8.8M
Q1 25
$83.3M
$4.8M
Q4 24
$83.0M
$11.0M
Q3 24
$88.5M
$8.4M
Q2 24
$89.2M
$19.7M
Q1 24
$93.8M
$46.2M
Total Debt
UTMD
UTMD
XOS
XOS
Q4 25
$225.0K
Q3 25
Q2 25
Q1 25
$269.0K
Q4 24
$282.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
UTMD
UTMD
XOS
XOS
Q4 25
$119.3M
$23.3M
Q3 25
$118.3M
$31.1M
Q2 25
$117.5M
$18.3M
Q1 25
$117.0M
$24.8M
Q4 24
$117.4M
$33.6M
Q3 24
$124.2M
$50.8M
Q2 24
$124.1M
$59.2M
Q1 24
$127.7M
$67.8M
Total Assets
UTMD
UTMD
XOS
XOS
Q4 25
$122.5M
$60.4M
Q3 25
$122.0M
$73.8M
Q2 25
$120.8M
$80.3M
Q1 25
$122.5M
$87.7M
Q4 24
$122.5M
$98.3M
Q3 24
$129.7M
$120.5M
Q2 24
$130.0M
$123.4M
Q1 24
$135.4M
$135.0M
Debt / Equity
UTMD
UTMD
XOS
XOS
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
UTMD
UTMD
XOS
XOS
Operating Cash FlowLast quarter
$3.5M
$2.4M
Free Cash FlowOCF − Capex
$3.4M
FCF MarginFCF / Revenue
37.2%
Capex IntensityCapex / Revenue
1.2%
0.0%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
UTMD
UTMD
XOS
XOS
Q4 25
$3.5M
$2.4M
Q3 25
$3.9M
$3.1M
Q2 25
$2.9M
$4.6M
Q1 25
$4.5M
$-4.8M
Q4 24
$2.9M
$3.3M
Q3 24
$3.9M
$-11.5M
Q2 24
$2.8M
$-26.0M
Q1 24
$5.3M
$-14.6M
Free Cash Flow
UTMD
UTMD
XOS
XOS
Q4 25
$3.4M
Q3 25
$3.9M
Q2 25
$2.8M
Q1 25
$4.3M
Q4 24
$2.9M
Q3 24
$3.8M
$-11.7M
Q2 24
$2.7M
$-26.1M
Q1 24
$5.3M
$-14.6M
FCF Margin
UTMD
UTMD
XOS
XOS
Q4 25
37.2%
Q3 25
39.2%
Q2 25
28.4%
Q1 25
44.1%
Q4 24
32.0%
Q3 24
37.7%
-73.9%
Q2 24
25.5%
-168.1%
Q1 24
46.3%
-115.7%
Capex Intensity
UTMD
UTMD
XOS
XOS
Q4 25
1.2%
0.0%
Q3 25
0.3%
0.0%
Q2 25
0.5%
0.0%
Q1 25
1.9%
0.0%
Q4 24
0.1%
0.0%
Q3 24
0.9%
0.9%
Q2 24
1.1%
0.8%
Q1 24
0.2%
0.2%
Cash Conversion
UTMD
UTMD
XOS
XOS
Q4 25
1.36×
Q3 25
1.47×
1.45×
Q2 25
0.94×
Q1 25
1.47×
Q4 24
1.01×
Q3 24
1.08×
Q2 24
0.80×
Q1 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons